Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System* as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.
December 28, 2023
· 6 min read
